Target intelligence / Profile preview

Cleavage and polyadenylation specificity factor subunit 3 (CPSF3)

Target
CPSF3
Molecular classification
Enzyme, Endonuclease, Component of multiprotein complex (CPSF complex), Metallo-β-lactamase family
01

Overview

Cleavage and polyadenylation specificity factor subunit 3 (CPSF3) is the endonuclease subunit of the cleavage and polyadenylation specificity factor (CPSF) complex, which is essential for the 3'-end processing of precursor mRNA in eukaryotic cells. CPSF3 specifically cleaves RNA at the polyadenylation site and contains a metallo-β-lactamase and β-CASP domain, coordinating two zinc ions necessary for activity. As the key enzyme responsible for producing mature mRNA 3'-termini, CPSF3 is crucial for mRNA maturation, alternative splicing, and regulation of gene expression. Overexpression or inhibition of CPSF3 affects tumor cell survival and has been implicated as a promising therapeutic target in acute myeloid leukemia, Ewing's sarcoma, lung adenocarcinoma, hepatocellular carcinoma, and other cancers. Germline biallelic mutations lead to severe neurodevelopmental syndromes. CPSF3’s essential function and unique enzymatic activity make it a focal point for drug development, mainly through targeted inhibition of its RNA endonuclease activity, but this approach may pose risks of widespread RNA processing defects in normal tissues [2,4,6,7].

Other names
CPSF-73CPSF73cleavage and polyadenylation specific factor 3
02

Mechanism of action

Inhibition of CPSF3 endonuclease activity blocks pre-mRNA cleavage, thereby disrupting mRNA maturation and cancer cell proliferation

03

Biological functions

pre-mRNA 3'-end processingRNA cleavagePolyadenylationmRNA maturationRegulation of alternative splicingCell cycle regulation
04

Disease associations

Cancer (notably lung adenocarcinoma and squamous cell carcinoma)Intellectual disability (with biallelic mutations)Hepatocellular carcinoma
05

Safety considerations

Potential for RNA processing disruption in normal cellsInherited biallelic loss-of-function variants cause severe neurodevelopmental disorders
06

Interacting drugs

Experimental inhibitors (e.g., compound 2 as characterized in preclinical studies); no FDA-approved drugs as of current knowledge
07

Biomarkers

CPSF3 expression (prognostic biomarker for non-small cell lung cancer, hepatocellular carcinoma, and potentially other cancers)

Beyond the preview

Go deeper on Cleavage and polyadenylation specificity factor subunit 3 (CPSF3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cleavage and polyadenylation specificity factor subunit 3 (CPSF3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call